Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ELAVL1 |
| Gene Name: | ELAVL1 |
| Protein Full Name: | ELAV-like protein 1 |
| Alias: | ELAV (embryonic lethal, abnormal vision)-like 1; ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R); ELAV1; ELAV-like 1; Embryonic lethal, abnormal vision, drosophila, homolog-like 1; Embryonic lethal, abnormal vision,-like 1; Hu antigen R; Hua; Hu-antigen R; HUR; MelG |
| Mass (Da): | 36092 |
| Number AA: | 326 |
| UniProt ID: | Q15717 |
| Locus ID: | 1994 |
| COSMIC ID: | ELAVL1 |
| Gene location on chromosome: | 19p13.2 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.41 |
| Normal role description: | Accumulated in the cytoplasm of extremely stressed cells. Ultimately leads to activation of the caspase-dependent apoptotic pathway. High levels of expression demonstrated in cancer cells but given known function, this appears to be a rescue mechanism against oncogenesis. |